PDF(Pubmed)
Abstract：
The Australian National COVID-19 Clinical Evidence Taskforce was established in March 2020 to maintain up-to-date recommendations for the treatment of people with coronavirus disease 2019 (COVID-19). The original guideline (April 2020) has been continuously updated and expanded from nine to 176 recommendations, facilitated by the rapid identification, appraisal, and analysis of clinical trial findings and subsequent review by expert panels.
In this article, we describe the recommendations for treating non-pregnant adults with COVID-19, as current on 1 August 2022 (version 61.0). The Taskforce has made specific recommendations for adults with severe/critical or mild disease, including definitions of disease severity, recommendations for therapy, COVID-19 prophylaxis, respiratory support, and supportive care.
The Taskforce currently recommends eight drug treatments for people with COVID-19 who do not require supplemental oxygen (inhaled corticosteroids, casirivimab/imdevimab, molnupiravir, nirmatrelvir/ritonavir, regdanvimab, remdesivir, sotrovimab, tixagevimab/cilgavimab) and six for those who require supplemental oxygen (systemic corticosteroids, remdesivir, tocilizumab, sarilumab, baricitinib, casirivimab/imdevimab). Based on evidence of their achieving no or only limited benefit, ten drug treatments or treatment combinations are not recommended; an additional 42 drug treatments should only be used in the context of randomised trials. Additional recommendations include support for the use of continuous positive airway pressure, prone positioning, and endotracheal intubation in patients whose condition is deteriorating, and prophylactic anticoagulation for preventing venous thromboembolism. The latest updates and full recommendations are available at www.covid19evidence.net.au.
In this article, we describe the recommendations for treating non-pregnant adults with COVID-19, as current on 1 August 2022 (version 61.0). The Taskforce has made specific recommendations for adults with severe/critical or mild disease, including definitions of disease severity, recommendations for therapy, COVID-19 prophylaxis, respiratory support, and supportive care.
The Taskforce currently recommends eight drug treatments for people with COVID-19 who do not require supplemental oxygen (inhaled corticosteroids, casirivimab/imdevimab, molnupiravir, nirmatrelvir/ritonavir, regdanvimab, remdesivir, sotrovimab, tixagevimab/cilgavimab) and six for those who require supplemental oxygen (systemic corticosteroids, remdesivir, tocilizumab, sarilumab, baricitinib, casirivimab/imdevimab). Based on evidence of their achieving no or only limited benefit, ten drug treatments or treatment combinations are not recommended; an additional 42 drug treatments should only be used in the context of randomised trials. Additional recommendations include support for the use of continuous positive airway pressure, prone positioning, and endotracheal intubation in patients whose condition is deteriorating, and prophylactic anticoagulation for preventing venous thromboembolism. The latest updates and full recommendations are available at www.covid19evidence.net.au.
摘要：
澳大利亚国家COVID-19临床证据工作组成立于2020年3月，旨在维持2019年冠状病毒病患者（COVID-19）治疗的最新建议。原指南(2020年4月)不断更新，从9条建议扩大到176条建议，通过快速识别，评估,以及对临床试验结果的分析以及随后由专家小组进行的审查。
在本文中,我们描述了2022年8月1日对COVID-19治疗非妊娠成人的建议(61.0版).工作组为患有严重/严重或轻度疾病的成年人提出了具体建议，包括疾病严重程度的定义，治疗建议，COVID-19预防，呼吸支持,和支持性护理。
工作组目前为不需要补充氧气的COVID-19患者推荐八种药物治疗（吸入皮质类固醇，casirivimab/imdevimab,Molnupiravir,nirmatrelvir/ritonavir,regdanvimab,remdesivir,sotrovimab,tixagevimab/cilgavimab）和6个用于需要补充氧气的人（全身性皮质类固醇，remdesivir,托珠单抗,sarilumab,baricitinib,casirivimab/imdevimab)。根据他们没有或只有有限的利益的证据，不推荐10种药物治疗或治疗组合;另外42种药物治疗仅应用于随机试验.其他建议包括支持使用持续气道正压通气，俯卧定位，以及病情恶化的患者的气管插管，预防静脉血栓栓塞的预防性抗凝治疗。最新更新和完整建议可在www上获得。covid19证据.net.au.
在本文中,我们描述了2022年8月1日对COVID-19治疗非妊娠成人的建议(61.0版).工作组为患有严重/严重或轻度疾病的成年人提出了具体建议，包括疾病严重程度的定义，治疗建议，COVID-19预防，呼吸支持,和支持性护理。
工作组目前为不需要补充氧气的COVID-19患者推荐八种药物治疗（吸入皮质类固醇，casirivimab/imdevimab,Molnupiravir,nirmatrelvir/ritonavir,regdanvimab,remdesivir,sotrovimab,tixagevimab/cilgavimab）和6个用于需要补充氧气的人（全身性皮质类固醇，remdesivir,托珠单抗,sarilumab,baricitinib,casirivimab/imdevimab)。根据他们没有或只有有限的利益的证据，不推荐10种药物治疗或治疗组合;另外42种药物治疗仅应用于随机试验.其他建议包括支持使用持续气道正压通气，俯卧定位，以及病情恶化的患者的气管插管，预防静脉血栓栓塞的预防性抗凝治疗。最新更新和完整建议可在www上获得。covid19证据.net.au.
